Use your antibodies-online credentials, if available.
Gankyrin expression promotes spontaneous cancer and non-cancerous liver diseases. Gankyrin accelerates liver steatosis, cholangitis, fibrosis, and hepatocarcinogenesis with persistent damage and proliferation in hepatocytes.
This study is the first to report gankyrin as a potential link between microRNAs and liver steatosis in zebrafish.
gankyrin alleviates oxidative stress via mTORC1 pathway activation.
the pro-malignant effects of Gankyrin in CRC cells
Low Gankyrin expression is associated with drug resistance in Breast Cancer.
the results demonstrated that the lentivirus-mediated shRNA vector-based RNAi expression system is an efficient method to silence PSMD10 gene expression in the MM RPMI-8226 cell line. It may provide a basis to study the role of PSMD10 in tumor cells, and may be a reliable gene therapy strategy in the clinic
Gankyrin sustains PI3K/GSK-3beta/beta-catenin signal activation and promotes an aggressive colorectal cancer phenotype and disease progression.
PSMD10/gankyrin has a role in inducing autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression
we conclude that FXR-Gank-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR-Gank-based therapy for treatment of patients with hepatoblastoma
p28 assists the proteolytic core particle to select a specific conformation of the ATPase ring for regulatory particle engagement and is released in a shoehorn-like fashion in the last step of the chaperone-mediated proteasome assembly.
gankyrin regulates HIF-1alpha protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation
The positive feedback regulation involving gankyrin and Nrf2 modulates a series of antioxidant enzymes, thereby lowering intracellular ROS and conferring a steadier intracellular environment, which prevents mitochondrial damage and cell death induced by excessive oxidative stress.
Gankyrin enhanced gastric cancer cell proliferation by regulating cell cycle-related proteins and by activating PI3K/AKT signaling pathway. Gankyrin played an important role in gastric carcinogenesis and could be a potential effective therapeutic target for enhancing chemosensitivity to 5-fluorouracil and cisplatin.
gankyrin is an oncoprotein that can be modified by small molecules in tumor cell lines
Gankyrin overexpression activates mTORC1 signaling and accelerating TSC2 degradation in colorectal tumor cells.
Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53. Gankyrin is involved in the regulation of cell signaling pathways, with particular reference to RhoA/ROCK/PTEN/PI3K/Akt, beta-catenin, IL-6/STAT3, and IL-1beta/IRAK-1 inflammatory signaling. Review.
Gankyrin-overexpressed non-small cell lung cancer patients had a significantly shorter survival time
Results identified rs111638916 SNP in the PSMD10 3'-UTR as a risk factor for gastric cancer (GC) and acted as a tumor promoting factor. SNP rs111638916 was also regulated by miR-505, resulting in its up-regulation in patients with GA and AA genotypes.
p28GANK expression was increased in metastatic ESCC tissues and cells, and p28GANK knockdown decreased the metastatic ability of ESCC cells.
This study identifies gankyrin, for the first time, as new potential predictive and oncogenic factor of well-differentiated/dedifferentiated liposarcoma, suggesting the potential for service as a future Liposarcoma therapeutic approach.
On the base results of present study one can suggests the p28GANK being useful as a predictive marker for patient prognosis and a novel therapeutic target for gastric cancer.
IL-1beta stimulation causes sequential phosphorylation of IRAK-1, c-Jun N-terminal kinase, and p300 and enhances recruitment of the p300/CBP/NF-Y complex to Gankyrin promoter
the present study clarified, at least partly, mechanisms of vascular tumorigenesis, and suggests that gankyrin might play a physiological role in hypoxic responses besides its roles as an oncoprotein.
FXR prevents liver cancer by inhibiting the gankyrin promoter via C/EBPbeta-HDAC1 complexes, leading to subsequent protection of tumor suppressor proteins from degradation.
Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis.
Findings suggest that retinoblastoma protein degradation in Lmna-/- cells occurs by gankyrin and MDM2-independent mechanisms.
Gankyrin oncoprotein has a role in progression of esophageal squamous cell carcinoma
This gene encodes a subunit of the PA700/19S complex, which is the regulatory component of the 26S proteasome. The 26S proteosome complex is required for ubiquitin-dependent protein degradation. This protein is a non-ATPase subunit that may be involved in protein-protein interactions. Aberrant expression of this gene may paly a role in tumorigenesis. Two transcripts encoding different isoforms have been described. Pseudogenes have been identified on chromosomes 3 and 20.
26S proteasome non-ATPase regulatory subunit 10
, proteasome 26S subunit, non-ATPase, 10
, 26S proteasome regulatory subunit p28
, ankyrin repeat protein
, hepatocellular carcinoma-associated protein p28-II
, proteasome subunit p28
, proteosome (prosome, macropain) 26S subunit, non-ATPase, 10
, proteosome subunit p28
, proteasome 26S non-ATPase subunit 10